Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,217.35 +31.64 (+2.67%)
Streaming Delayed Price Updated: 1:43 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
News headline image
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About ↗
The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments. 
Via The Motley Fool
News headline image
These 3 Stocks With Fast-Growing Dividends Can Help You Beat Inflation ↗
Eli Lilly, Parker-Hannifin, and Microsoft all have grown their dividend by 50% or more over the past five years, but still have plenty of room for dividend growth. 
Via The Motley Fool
Topics Economy
News headline image
American Express, Live Nation And A Health Care Stock: CNBC's 'Final Trades' ↗
Eli Lilly and American Express are top picks on CNBC's Halftime Report Final Trades. Live Nation is on the verge of a new 52-week high. 
Via Benzinga
News headline image
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend. ↗
New cancer therapies may help fund dividend growth. 
Via The Motley Fool
Topics Intellectual Property
Eli Lilly & Co (NYSE:LLY): An Affordable Growth Opportunity in the Pharmaceutical Sector ↗
Via Chartmill
News headline image
Is Viking Therapeutics Stock Going to $100? ↗
Viking stock is known for soaring after positive news. 
Via The Motley Fool
News headline image
2 Cash-Producing Stocks on Our Buy List and 1 That Underwhelm
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas... 
Via StockStory
News headline image
Why Pfizer Stock Popped Today ↗
Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell. 
Via The Motley Fool
News headline image
2 Profitable Stocks for Long-Term Investors and 1 Facing Headwinds
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
Why Eli Lilly Stock Climbed to a New All-Time High Today ↗
The pharma giant is well-positioned to lead the $200 billion global obesity treatment market. 
Via The Motley Fool
News headline image
Prediction: The Trump Bull Market Will Soon End -- But These 2 Stocks Will Keep Winning Anyway ↗
These stocks may deliver gains during any market environment. 
Via The Motley Fool
Topics Artificial Intelligence Government Initial Public Offering
News headline image
Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy? ↗
Infectious disease could fuel Eli Lilly's next growth phase. 
Via The Motley Fool
News headline image
Stock Market Today, June 8: Marvell, Intel, and Micron Lead Tech Stock Rebound ↗
Marvell’s leap into the S&P 500 caps a sharp AI-chip rebound that helped steady U.S. stocks, today, June 8, 2026. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
Why Eli Lilly (LLY) Stock Is Up Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.1% in the afternoon session after the company reported positive Phase 3 ... 
Via StockStory
News headline image
Why Eli Lilly, In A Buy Zone, Is Still The 'Clear Winner' Of The 'Weight Loss Olympics' ↗
Eli Lilly emerged as the "clear winner" from the ADA meeting last weekend in New Orleans, an analyst said following the event. 
Via Investor's Business Daily
News headline image
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk. ↗
Zealand Pharma's stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug. 
Via The Motley Fool
News headline image
Is the Vanguard Growth ETF (VUG) the Right Fit for Your Portfolio? ↗
How does an average annual gain of 18% over the past decade sound? 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages ↗
Eli Lilly reports Foundayo delivered significant weight loss across menopausal stages, with up to 14.4% reductions at 72 weeks. 
Via Benzinga
News headline image
Want to Avoid SpaceX, Anthropic, and OpenAI? Buy This Low-Cost Vanguard ETF. ↗
Getting exposure to high-profile IPOs is easier than ever through low-cost index funds and ETFs. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
Eli Lilly Could Become The World's Top AI Firm? Jordi Visser Has Reasons To Believe Mounjaro Maker Could Become The Largest Company Globally ↗
Investor Jordi Visser says Eli Lilly could become the world's largest company and AI leader within five years due to its AI advantage. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Q1 Earnings Review: Branded Pharmaceuticals Stocks Led by Eli Lilly (NYSE:LLY)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Want Nothing to Do With SpaceX? Buy This Ultra-Low-Cost Dividend Growth ETF in June. ↗
The Vanguard Dividend Appreciation ETF is the perfect fit for investors looking to build a portfolio around high-quality companies that pay growing dividends. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case? ↗
Novo Nordisk could maintain this latest early-mover advantage longer than you think. 
Via The Motley Fool
News headline image
Micron Makes the $1 Trillion Club a Little More Crowded ↗
Micron has had a turnaround for the ages, going from a free cash flow negative company to a $1 trillion valuation in a little over a year. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are Missing ↗
Eli Lilly just announced a trio of acquisitions that will allow it to build a new business focused on infectious diseases. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems ↗
Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Prediction: Eli Lilly Will Reach $1,200 in 2026 ↗
International growth could help push Lilly even higher. 
Via The Motley Fool
News headline image
Novo's Wegovy Pill Isn't Just Beating Expectations -- It's Obliterating Them. Is the Beaten-Down Stock a Buy Now? ↗
Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Leads Medical Stocks To Watch, While Google Finds Support ↗
The stock market appears to be rotating into health care. 
Via Investor's Business Daily
News headline image
Here's How Much $1000 Invested In Eli Lilly 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.